Cristina Quintavalle
@ieos.cnr.it
IEOS-CNR
Scopus Publications
- Colorimetric aptasensor for exosome detection in breast cancer liquid biopsy
Bartolomeo Della Ventura, Cristina Quintavalle, Erica Cavaliere, Kristin Tkalčec, Paolo Aniello, Vincenzo Iannotti, Gerolama Condorelli, Raffaele Velotta
Sensors and Actuators B Chemical, 2026
Exosomes are nanoscale extracellular vesicles (EVs) that carry molecular signatures reflective of their cells of origin, making them attractive biomarkers for liquid biopsy applications. In this study, we present a rapid and highly specific colorimetric aptasensor for the detection of Gremlin-1 (GREM1)-expressing exosomes in serum. The sensing strategy relies on the disaggregation of gold nanoparticle (AuNP) clusters, initially formed by NaCl-induced aggregation, upon selective binding of the target. AuNPs were functionalized with a thiolated Ex.50.T aptamer specifically recognizing exosomal GREM1, and the binding event triggers a measurable spectral shift in the plasmonic profile. A detection limit below 10 6 exosomes/mL was achieved using serial dilutions of purified exosomes isolated from breast cancer serum samples, demonstrating the method’s sensitivity and robustness under controlled conditions. Applied to 100 clinical serum samples, the assay demonstrated excellent diagnostic performance, with 84% sensitivity and 90% specificity—values comparable to those of mammography—without requiring extensive sample processing. Comparative analysis with commercial ELISA and Ex.50.T aptamer-based ELONA confirmed the superior discriminatory power of the method proposed here. Transmission electron microscopy further corroborated the mechanism by revealing exosomes physically disrupting AuNP aggregates. These results highlight the diagnostic potential of exosome-focused sensing strategies and establish this aptamer-based colorimetric platform as a promising candidate for non-invasive screening of breast cancer through liquid biopsy. • Colorimetric aptasensor discriminates breast cancer serum with 84% sensitivity, 90% specificity • Simple optical test matches mammography performance in liquid biopsy for breast cancer • Mix-and-measure detection of tumor-derived exosomes in 1:1 diluted serum • Anti-aggregation assay detects GREM-1-positive exosomes with high diagnostic accuracy • TEM imaging is consistent with exosome-induced disaggregation of gold nanoparticle clusters - Sex-related susceptibility to pulmonary fibrosis development in mice
Danilo D'Avino, Ida Cerqua, Lucianna Maruccio, Katharina P. L. Meyer, Cristina Quintavalle, Simona Pace, Martina Simonelli, Patrick Schädel, Sara Perna, Elisabetta Granato, Myrhiam Cassese, Domenico Galati, Fabio Cattaneo, Armando Ialenti, Oliver Werz, Marialuisa Bocchino, Fiorentina Roviezzo, Antonietta Rossi
British Journal of Pharmacology, 2026
Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease, mainly affecting adult males. Although it exhibits a primarily fibrosing imprint, it serves as a model for understanding inflammation‐driven interstitial lung diseases that can evolve into PF. We analysed the interplay between inflammation and fibrosis, in relation to sex in a mouse model of PF. Experimental Approach Adult C57BL/6 mice of both sexes were treated with subcutaneous bleomycin injection (3 times a week for 1–4 weeks). We used RT‐PCR, western blotting and immunohistochemistry, along with ELISA, flow cytometry and mass spectrometry (UPLC‐MS/MS) to analyse our results. Key Results Male mice developed more severe fibrosis, with higher levels of collagen, and enhanced pulmonary epithelial–mesenchymal transition, compared with females. Males also showed early cell infiltration (neutrophils and macrophages) during the initial stages, followed by loss of lung architecture and an exacerbated development of fibrosis. In contrast, females exhibited physiological resolution of lung inflammation after 2 weeks of bleomycin treatment. In males, PF was associated with increased pro‐inflammatory/fibrotic mediators (TGF‐β and IL‐1β) and decreased anti‐inflammatory/anti‐fibrotic factors (IFN‐γ, miRNA‐214‐3p, miRNA‐96‐5p and PGE 2 ), particularly in the early phase of fibrosis. Pre‐treatment with pirfenidone reversed fibrosis features more effectively in males, impacting anti‐fibrotic miRNA‐214‐3p and miRNA‐96‐5p. Conclusions and Implications Our data suggest that while inflammation occurs in both males and females during the early stages of PF induction, exacerbated fibrosis is observed only in males. Additionally, pirfenidone demonstrated greater activity in male mice, highlighting the need to consider potential sex‐specific pharmacotherapy. - Operator-dependent and operator-independent contrast media minimization strategies to prevent acute kidney injury after percutaneous coronary intervention
Luca PAOLUCCI, Valeria CAVALIERE, Francesca DE MICCO, Mario SCARPELLI, Amelia FOCACCIO, Cristina QUINTAVALLE, Carlo BRIGUORI
Minerva Cardiology and Angiology, 2026
Contrast associated acute kidney injury (CA-AKI) is a major complication of contrast media (CM) exposure following percutaneous coronary intervention (PCI), associated with high rates of morbidity and mortality in both early and late phases. During the past years, several CA-AKI prevention strategies based on CM sparing have been proposed, which differ significantly in terms of methodological features and efficacy. In this review, we propose a new classification of these techniques based on their dependency on operators' management. Following, we summarize current evidence on the effectiveness in terms of CA-AKI reduction of each one of the currently available operator-dependent and -independent CM minimization strategies. - Proteomic profiling of extracellular vesicles in ST-elevation acute myocardial infarction
Cristina Quintavalle, Giuseppina Roscigno, Gianluca Petrillo, Luca Paolucci, Mario Scarpelli, Amelia Focaccio, Mariateresa Librera, Katia Pane, Monica Franzese, Silvia Nuzzo, Alessandra Affinito, Giuseppe Biondi Zoccai, Francesca De Micco, Zoran Minic, Maxim V Berezovski, Carlo Briguori, Gerolama Condorelli
Cardiovascular Research, 2026 - Fibroblasts activated by miRs-185-5p, miR-652-5p, and miR-1246 shape the tumor microenvironment in triple-negative breast cancer via PATZ1 downregulation
Giada De Luca, Gianluca Petrillo, Iolanda Scognamiglio, Katia Pane, Lorenza Cocca, Giuseppina Roscigno, Martina Mascolo, Claudia Pignataro, Sara Verde, Aurelia Fraticelli, Danilo Fiore, Alessandra Affinito, Silvia Nuzzo, Zoran Minic, Francesca De Micco, Guglielmo Thomas, Monica Franzese, Maxim V. Berezovski, Monica Fedele, Gerolama Condorelli, Cristina Quintavalle
Cellular and Molecular Life Sciences, 2025
The intricate interplay between epithelial and fibroblast cells within the tumor microenvironment plays a crucial role in driving triple-negative breast cancer progression. This crosstalk involves the exchange of various signaling molecules, including growth factors, cytokines, extracellular matrix components, and extracellular vesicles. Recently, we demonstrated that triple-negative breast cancer extracellular vesicles carry and release a specific combination of miRs, including miR-185-5p, miR-652-5p, and miR-1246 (from here on, referred as combo-miRs), into normal fibroblasts, effectively reprogramming them into cancer-associated fibroblasts. Here, we show that the conditioned medium from the fibroblasts activated by combo-miRs exerts a pro-tumorigenic effect on epithelial cells, enhancing the viability and migratory potential while driving increased invasiveness in patient-derived breast cancer organoids. A proteomic analysis of conditioned medium from combo-miRs activated fibroblasts revealed 76 significantly upregulated secreted proteins compared to control. Bioinformatic analysis identified the transcriptional factor PATZ1 as a potential regulator of the 12 most highly upregulated proteins. Consistently, in-silico predictions and in vitro experiments confirmed that PATZ1 is a direct target of miR-185-5p and miR-652-5p. The downregulation of PATZ1 by these miRNAs led to increased levels of the secreted proteins in the conditioned medium from combo-miRs activated fibroblasts. Furthermore, the conditioned medium from PATZ1-knockout mesenchymal embryonic fibroblasts and normal fibroblasts with silenced PATZ1 similarly enhanced the migratory potential of MCF10A cells, further supporting the critical role of PATZ1 in regulating tumor-promoting mechanisms. These findings provide valuable insights into the dynamics of the TME in TNBC, highlighting combo-miRs and PATZ1 as promising targets for future therapeutic interventions. - Ex.50.T aptamer impairs tumor–stroma cross-talk in breast cancer by targeting gremlin-1
Cristina Quintavalle, Francesco Ingenito, Giuseppina Roscigno, Birlipta Pattanayak, Carla Lucia Esposito, Alessandra Affinito, Danilo Fiore, Gianluca Petrillo, Silvia Nuzzo, Bartolomeo Della Ventura, Federica D’Aria, Concetta Giancola, Stefania Mitola, Elisabetta Grillo, Marinella Pirozzi, Greta Donati, Francesco Saverio Di Leva, Luciana Marinelli, Zoran Minic, Francesca De Micco, Guglielmo Thomas, Maxim V. Berezovski, Gerolama Condorelli
Cell Death Discovery, 2025
The tumor microenvironment profoundly influences tumor complexity, particularly in breast cancer, where cancer-associated fibroblasts play pivotal roles in tumor progression and therapy resistance. Extracellular vesicles are involved in mediating communication within the TME, specifically highlighting their role in promoting the transformation of normal fibroblasts into cancer-associated fibroblasts. Recently, we identified an RNA aptamer, namely ex.50.T, that binds with remarkable affinity to extracellular vesicles shed from triple-negative breast cancer cells. Here, through in vitro assays and computational analyses, we demonstrate that the binding of ex.50.T to extracellular vesicles and parental breast cancer cells is mediated by recognition of gremlin-1 (GREM1), a bone morphogenic protein antagonist implicated in breast cancer aggressiveness and metastasis. Functionally, we uncover the role of ex.50.T as an innovative therapeutic agent in the process of tumor microenvironment re-modeling, impeding GREM1 signaling, blocking triple-negative breast cancer extracellular vesicles internalization in recipient cells, and counteracting the transformation of normal fibroblasts into cancer-associated fibroblasts. Altogether, our findings highlight ex.50.T as a novel therapeutical avenue for breast cancer and potentially other GREM1-dependent malignancies, offering insights into disrupting TME dynamics and enhancing cancer treatment strategies. - BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma
Claudia Pignataro, Pietro Zoppoli, Luca Vincenzo Cappelli, Liron Yoffe, Marta Moretti, Mariapaola Izzo, Selene Mallia, Clarisse Kayembe, Abigail Taylor, Gianluca Petrillo, Alessandra Affinito, Cristina Quintavalle, Giada De Luca, Martina Mascolo, Sara Verde, Aurelia Fraticelli, Alessia Ciarrocchi, Paolo Salerno, Enrico De Smaele, Antonio Francesco Campese, Valentina Fragliasso, Robin Foà, Giuseppe Merla, Giorgio Inghirami, Gerolama Condorelli, Danilo Fiore
Blood Advances, 2025
Resistance to first-line chemotherapies and crizotinib in anaplastic large cell lymphoma (ALCL) represents a significant challenge, often leading to a dismal outcome. Despite recent advancements, the dissection of the intrinsic and extrinsic molecular alterations underlying crizotinib resistance in ALCL is still poorly understood. Here, we transcriptionally unraveled the bidirectional interplay between anaplastic lymphoma kinase (ALK)-driven ALCL (ALK+ ALCL) and stromal cells in the presence of crizotinib at bulk and single-cell levels and identified that the microenvironment provides prosurvival signals leading to crizotinib persistence in ALK+ ALCL. We detected increased B-cell lymphoma 2 (BCL2) expression and downregulation of pathways related to apoptosis in crizotinib-persister ALK+ ALCL cells. Furthermore, we predicted in silico the ligand-receptor interactions between tumoral and stromal cells, supporting their contribution to ALCL pathogenesis mainly participating in the adhesion/membrane transport, triggering receptors, and promoting activation and microenvironment stimulation in lymphoma cells. Finally, we explored the effect of crizotinib in combination with BH3 mimetics. Pharmacologic and genetic ablation of anti-apoptotic targets displayed a significant synergistic effect with crizotinib, overcoming the stroma-mediated protection of lymphoma cells on drug treatment. Thus, BCL2/B-cell lymphoma-extra large (BCL-XL) targeting is synthetic lethal with crizotinib exposure in ALK+ ALCL and represents an intrinsic- and extrinsic-mediated targetable vulnerability in lymphoma cells challenged with crizotinib. Our data support the evaluation of BCL2 targeting in crizotinib-based regimens in the management of patients with ALK+ ALCL. - Targeting Glioblastoma Stem Cells via EphA2: Structural Insights into the RNA Aptamer A40s for Precision Therapy
Isidora Diakogiannaki, Vincenzo Maria D’Amore, Alessandra Affinito, Greta Donati, Elpidio Cinquegrana, Cristina Quintavalle, Martina Mascolo, Jule Walter, Heike Betat, Mario Mörl, Francesco Saverio Di Leva, Gerolama Condorelli, Luciana Marinelli
Journal of Chemical Information and Modeling, 2025
EphA2 receptor tyrosine kinase is overexpressed in many solid tumors and serves as a key driver of tumorigenesis and metastasis. It is highly expressed in glioblastoma multiforme, the most aggressive brain tumor in adults, and in its stem cells [glioblastoma stem cells (GSCs)], which contribute to treatment resistance and tumor relapse. In a previous study, we used the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) procedure, a method for selecting high-affinity nucleic acids to specific targets via iterative selection and amplification, to identify the 2'-fluorinated EphA2-targeting RNA aptamer A40L and a truncated 30-mer derivative, A40s. Both aptamers were able to inhibit GSC growth, stemness, and migration upon EphA2 binding. Here, by integrating computational and experimental methods, the A40s structure was unraveled and its interaction with EphA2 was investigated. Our model offers a blueprint to accelerate the development of optimized A40s variants, advancing next-generation EphA2-targeted anticancer therapies. - Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment
Alessandra Affinito, Francesco Ingenito, Sara Verde, Emanuele Musella, Birlipta Pattanayak, Danilo Fiore, Cristina Quintavalle, Aurelia Fraticelli, Martina Mascolo, Gianluca Petrillo, Claudia Pignataro, Giada De Luca, Laura Mezzanotte, Gerolama Condorelli
Biomolecules, 2025
Glioblastoma (GBM) is the most aggressive and challenging brain cancer, in terms of diagnosis and therapy. The highly infiltrative glioblastoma stem cells (GSCs) are difficult to visualize and surgically remove with the current diagnostic tools, which often lead to misdiagnosis and false-positive results. In this study, we focused on a groundbreaking tool for specifically visualizing and removing GSCs. We exploited the specific binding of A40s aptamer to EphA2 for the selective delivery of Near-Infrared Dyes (NIR-Dyes), like IR700DX and ICG, both in vitro and in vivo. The A40s aptamer, engineered through the NIR-Dye conjugation, did not affect aptamer binding ability; indeed, A40s-NIR-Dye conjugates bound GLI261 stem-like cells and patient-derived GSCs in vitro; moreover, they induced cell death upon photodynamic therapy treatment (PDT). Additionally, when systemically administrated, the A40s-NIR-Dye conjugates allowed GSC visualization and accumulated in tumor mass. This allows GSCs detection and treatment. Our findings demonstrate the potential use of A40s aptamer as a targeted therapeutic approach and imaging tool in vivo for GSCs, paving the way for improved, more effective, and less invasive GBM management. - The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response
Cristina Quintavalle, Umberto Malapelle, Marco De Martino, Danilo Rocco, Alfredo Fusco, Francesco Pepe, Claudio Bellevicine, Francesco Esposito, Pierlorenzo Pallante
Genes, 2025
Background/Objectives: The UbcH10 protein plays an important role in a variety of human malignancies, including thyroid, breast, ovarian, and colorectal carcinomas. It has been previously reported that UbcH10 is overexpressed in non-small cell lung cancer (NSCLC) compared to normal lungs and that its expression is directly and inversely correlated with the mutational status of p53 and EGFR, respectively. Methods: We transfected lung cancer cells with wild-type and mutant forms of EGFR, modulated the expression of UbcH10 and p53, and treated these cells with tyrosine kinase inhibitor (TKI) erlotinib. Using Western blotting, we evaluated the expression of UbcH10 induced by EGFR and p53. Finally, we employed immunohistochemistry to assess the levels of UbcH10 expression in a subset of NSCLC patients receiving TKI therapy. Results: We reported a possible modulation of UbcH10 expression by the overexpression of wild-type and mutant EGFR in H460 lung cancer cells, potentially through p53. The enforced expression of UbcH10 in cells transfected with mutant EGFR suggested a potential increase in resistance to erlotinib treatment. Finally, immunohistochemical analysis of samples from NSCLC patients with mutant EGFR indicated a possible connection between UbcH10 expression levels and progression-free survival. Conclusions: In NSCLC, UbcH10 may play a role in the regulation of TKI response via a molecular pathway potentially involving p53 and EGFR. However, further research is needed to fully understand this mechanism. - Extracellular vesicles and microRNAs in cancer progression
Nicola Salvatore Orefice, Gianluca Petrillo, Claudia Pignataro, Martina Mascolo, Giada De Luca, et al.
Advances in Clinical Chemistry, 2025 - MCT4-driven CAF-mediated metabolic reprogramming in breast cancer microenvironment is a vulnerability targetable by miR-425-5p
Alessandra Affinito, Cristina Quintavalle, Rosario Vincenzo Chianese, Giuseppina Roscigno, Danilo Fiore, Valeria D’Argenio, Guglielmo Thomas, Alessia Savarese, Francesco Ingenito, Lorenza Cocca, Silvia Nuzzo, Maxim V. Berezovski, Maria Patrizia Stoppelli, Gerolama Condorelli
Cell Death Discovery, 2024 - Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers
Annamaria Salvati, Giorgio Giurato, Jessica Lamberti, Ilaria Terenzi, Laura Crescenzo, Viola Melone, Luigi Palo, Alessandro Giordano, Francesco Sabbatino, Giuseppina Roscigno, Cristina Quintavalle, Gerolama Condorelli, Francesca Rizzo, Roberta Tarallo, Giovanni Nassa, Alessandro Weisz
Molecular Cancer, 2024 - Ultrasmall Carbon Nanodots as Theranostic Nanoheaters for Precision Breast Cancer Phototherapy: Establishing the Translational Potential in Tumor-in-a-Dish Models
Giuseppina Roscigno, Alessandra Affinito, Cristina Quintavalle, Roberta Cillari, Gerolama Condorelli, Gennara Cavallaro, Nicolò Mauro
ACS Biomaterials Science and Engineering, 2024 - The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma
Carolina Giordano, Laura Marrone, Simona Romano, Giuseppe Maria Della Pepa, Carlo Maria Donzelli, Martina Tufano, Mario Capasso, Vito Alessandro Lasorsa, Cristina Quintavalle, Giulia Guerri, Matia Martucci, Annamaria Auricchio, Marco Gessi, Evis Sala, Alessandro Olivi, Maria Fiammetta Romano, Simona Gaudino
Cancer Research Communications, 2024 - Erratum to: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer (Oncogene, (2008), 27, 27, (3845-3855), 10.1038/onc.2008.6)
M. Garofalo, C. Quintavalle, G. Di Leva, C. Zanca, G. Romano, C. Taccioli, C. G. Liu, C. M. Croce, G. Condorelli
Oncogene, 2024 - Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes
Carlo Briguori, Cristina Quintavalle, Enrica Mariano, Alessandro D’Agostino, Mario Scarpelli, Amelia Focaccio, Giuseppe Biondi Zoccai, Salvatore Evola, Giovanni Esposito, Giuseppe Massimo Sangiorgi, Gerolama Condorelli
Journal of the American College of Cardiology, 2024 - Selection of RNA aptamers targeting hypoxia in cancer
Silvia Nuzzo, Margherita Iaboni, Maria Luigia Ibba, Anna Rienzo, Domenica Musumeci, Monica Franzese, Giuseppina Roscigno, Alessandra Affinito, Gianluca Petrillo, Cristina Quintavalle, Giuseppe Ciccone, Carla Lucia Esposito, Silvia Catuogno
Frontiers in Molecular Biosciences, 2022 - Erratum: Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer (Molecular Therapy - Nucleic Acids (2022) 28 (17–31), (S2162253122000415), (10.1016/j.omtn.2022.02.013))
Iolanda Scognamiglio, Lorenza Cocca, Ilaria Puoti, Francesco Palma, Francesco Ingenito, Cristina Quintavalle, Alessandra Affinito, Giuseppina Roscigno, Silvia Nuzzo, Rosario Vincenzo Chianese, Stefania Belli, Guglielmo Thomas, Timo Schomann, Alan Chan, Maria Patrizia Stoppelli, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2022 - Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer
Iolanda Scognamiglio, Lorenza Cocca, Ilaria Puoti, Francesco Palma, Francesco Ingenito, Cristina Quintavalle, Alessandra Affinito, Giuseppina Roscigno, Silvia Nuzzo, Rosario Vincenzo Chianese, Stefania Belli, Guglielmo Thomas, Timo Schomann, Alan Chan, Maria Patrizia Stoppelli, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2022 - miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase–Protein Kinase B Pathway in Chronically Inflamed Liver
Cristina Quintavalle, Nathalie Meyer‐Schaller, Stephanie Roessler, Diego Calabrese, Romina Marone, Tobias Riedl, Silvia Picco‐Rey, Orestis A. Panagiotou, Sarp Uzun, Salvatore Piscuoglio, Tuyana Boldanova, Chaoran B. Bian, David Semela, Wolfram Jochum, Gieri Cathomas, Kirsten D. Mertz, Joachim Diebold, Luca Mazzucchelli, Viktor H. Koelzer, Achim Weber, Thomas Decaens, Luigi M. Terracciano, Mathias Heikenwalder, Yujin Hoshida, Jesper B. Andersen, Snorri S. Thorgeirsson, Matthias S. Matter
Hepatology Communications, 2022 - Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study
Katia Pane, Cristina Quintavalle, Silvia Nuzzo, Francesco Ingenito, Giuseppina Roscigno, Alessandra Affinito, Iolanda Scognamiglio, Birlipta Pattanayak, Enrico Gallo, Antonella Accardo, Guglielmo Thomas, Zoran Minic, Maxim V. Berezovski, Monica Franzese, Gerolama Condorelli
International Journal of Molecular Sciences, 2022 - The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors
Marco De Martino, Simona Pellecchia, Francesco Esposito, Nadia Tosti, Cristina Quintavalle, Serenella Eppenberger-Castori, Vincenza Carafa, Alberto Righi, Paolo Chieffi, Alfredo Fusco, Luigi Maria Terracciano, Pierlorenzo Pallante
Cell Cycle, 2022 - ZNF224 is a mediator of TGF-β pro-oncogenic function in melanoma
Elena Cesaro, Arianna Pastore, Alessia Polverino, Lorenzo Manna, Giuseppina Divisato, Cristina Quintavalle, Maddalena Di Sanzo, Maria Concetta Faniello, Michela Grosso, Paola Costanzo
Human Molecular Genetics, 2021 - Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors
Pasquale Russomanno, Giulia Assoni, Jussara Amato, Vincenzo Maria D’Amore, Riccardo Scaglia, Diego Brancaccio, Martina Pedrini, Giovanna Polcaro, Valeria La Pietra, Paolo Orlando, Marianna Falzoni, Linda Cerofolini, Stefano Giuntini, Marco Fragai, Bruno Pagano, Greta Donati, Ettore Novellino, Cristina Quintavalle, Gerolama Condorelli, Francesco Sabbatino, Pierfausto Seneci, Daniela Arosio, Stefano Pepe, Luciana Marinelli
Journal of Medicinal Chemistry, 2021 - Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma
Dominik Witzigmann, Philip Grossen, Cristina Quintavalle, Manuela Lanzafame, Susanne H. Schenk, Xue-Ting Tran, Bernhard Englinger, Patrick Hauswirth, David Grünig, Sushilla van Schoonhoven, Stephan Krähenbühl, Luigi M. Terracciano, Walter Berger, Salvatore Piscuoglio, Luca Quagliata, Jean Rommelaere, Jürg P.F. Nüesch, Jörg Huwyler
Journal of Controlled Release, 2021 - Urinary Dickkopf-3 and Contrast-Associated Kidney Damage
Giuseppina Roscigno, Cristina Quintavalle, Giuseppe Biondi-Zoccai, Francesca De Micco, Giacomo Frati, Alessandra Affinito, Silvia Nuzzo, Gerolama Condorelli, Carlo Briguori
Journal of the American College of Cardiology, 2021 - miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer
Francesco Palma, Alessandra Affinito, Silvia Nuzzo, Giuseppina Roscigno, Iolanda Scognamiglio, Francesco Ingenito, Lola Martinez, Monica Franzese, Mario Zanfardino, Andrea Soricelli, Alfonso Fiorelli, Gerolama Condorelli, Cristina Quintavalle
Cancer Gene Therapy, 2021 - Identification of a novel RNA aptamer that selectively targets breast cancer exosomes
Carla Lucia Esposito, Cristina Quintavalle, Francesco Ingenito, Deborah Rotoli, Giuseppina Roscigno, Silvia Nuzzo, Renato Thomas, Silvia Catuogno, Vittorio de Franciscis, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2021 - Correction: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer (Oncogene, (2008), 27, 27, (3845-3855), 10.1038/onc.2008.6)
M. Garofalo, C. Quintavalle, G. Di Leva, C. Zanca, G. Romano, C. Taccioli, C. G. Liu, C. M. Croce, G. Condorelli
Oncogene, 2021 - MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells
Simona Pellecchia, Marco De Martino, Francesco Esposito, Cristina Quintavalle, Alfredo Fusco, Pierlorenzo Pallante
Cell Cycle, 2021 - Targeting breast cancer exosomes with nucleic aptamers: Innovative tools for early diagnosis and therapy
Siberian Medical Review, 2021 - Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731] (Neoplasia (2016) 18(12) (724–731), (S1476558616301634), (10.1016/j.neo.2016.10.002))
Mariacarla Andreozzi, Cristina Quintavalle, David Benz, Luca Quagliata, Matthias Matter, Diego Calabrese, Nadia Tosti, Christian Ruiz, Francesca Trapani, Luigi Tornillo, Alfredo Fusco, Markus H. Heim, Charlotte K.Y. Ng, Pierlorenzo Pallante, Luigi M. Terracciano, Salvatore Piscuoglio
Neoplasia United States, 2020 - Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells
Alessandra Affinito, Cristina Quintavalle, Carla Lucia Esposito, Giuseppina Roscigno, Catello Giordano, Silvia Nuzzo, Lucia Ricci-Vitiani, Iolanda Scognamiglio, Zoran Minic, Roberto Pallini, Maxim V. Berezovski, Vittorio de Francisis, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2020 - MiR-216a acts as a negative regulator of breast cancer by modulating stemness properties and tumor microenvironment
Giuseppina Roscigno, Assunta Cirella, Alessandra Affinito, Cristina Quintavalle, Iolanda Scognamiglio, Francesco Palma, Francesco Ingenito, Silvia Nuzzo, Francesca De Micco, Antonio Cuccuru, Renato Thomas, Gerolama Condorelli
International Journal of Molecular Sciences, 2020 - The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells
Alessandra Affinito, Cristina Quintavalle, Carla Lucia Esposito, Giuseppina Roscigno, Claudia Vilardo, Silvia Nuzzo, Lucia Ricci-Vitiani, Gabriele De Luca, Roberto Pallini, Anna S. Kichkailo, Ivan N. Lapin, Vittorio de Franciscis, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2019 - Convergent Evolution of Copy Number Alterations in Multi-Centric Hepatocellular Carcinoma
Carolin Lackner, Luca Quagliata, William Cross, Sebastian Ribi, Karl Heinimann, Viola Paradiso, Cristina Quintavalle, Monika Kovacova, Daniel Baumhoer, Salvatore Piscuoglio, Luigi Terracciano, Michal Kovac
Scientific Reports, 2019 - Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer
Silvia Nuzzo, Giuseppina Roscigno, Alessandra Affinito, Francesco Ingenito, Cristina Quintavalle, Gerolama Condorelli
Cancers, 2019 - The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications
Francesco Ingenito, Giuseppina Roscigno, Alessandra Affinito, Silvia Nuzzo, Iolanda Scognamiglio, Cristina Quintavalle, Gerolama Condorelli
International Journal of Molecular Sciences, 2019 - Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply
Carlo Briguori, Cristina Quintavalle, Michael Donahue, Francesca D'Alessio, Carmen D'Amore, Giuseppe Signoriello, Raffaele De Caterina, Gerolama Condorelli
International Journal of Cardiology, 2019 - Predictors of strut coverage of drug eluting stent implantation in diabetic patients
Carlo Briguori, Cristina Quintavalle, Michael Donahue, Francesca D'Alessio, Carmen D'Amore, Giuseppe Signoriello, Luigi del Vecchio, Raffaele De Caterina, Gerolama Condorelli
International Journal of Cardiology, 2019 - The control of tumor progression by circular RNAs: Novel prognostic and therapeutic insights resulting from the analysis of the circAGO2/human antigen R complex
Simona Pellecchia, Cristina Quintavalle, Pierlorenzo Pallante
Translational Cancer Research, 2019 - Persistent serum creatinine increase following contrast-induced acute kidney injury
Carlo Briguori, Cristina Quintavalle, Francesca De Micco, Gabriella Visconti, Vito Di Palma, Giovanni Napolitano, Amelia Focaccio, Gerolama Condorelli
Catheterization and Cardiovascular Interventions, 2018 - Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance
Joël R Federer-Gsponer, Cristina Quintavalle, David C Müller, Tanja Dietsche, Valeria Perrina, Thomas Lorber, Darius Juskevicius, Elisabeth Lenkiewicz, Tobias Zellweger, Thomas Gasser, Michael T Barrett, Cyrill A Rentsch, Lukas Bubendorf, Christian Ruiz
Journal of Pathology, 2018 - Genetic profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma patients: A pilot study
C.K.Y. Ng, G.G. Di Costanzo, N. Tosti, V. Paradiso, M. Coto-Llerena, G. Roscigno, V. Perrina, C. Quintavalle, T. Boldanova, S. Wieland, G. Marino-Marsilia, M. Lanzafame, L. Quagliata, G. Condorelli, M.S. Matter, R. Tortora, M.H. Heim, L.M. Terracciano, S. Piscuoglio
Annals of Oncology, 2018 - High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models
Luca Quagliata, Cristina Quintavalle, Manuela Lanzafame, Matthias S Matter, Chiara Novello, Luca di Tommaso, Tiziana Pressiani, Lorenza Rimassa, Luigi Tornillo, Massimo Roncalli, Clemente Cillo, Pierlorenzo Pallante, Salvatore Piscuoglio, Charlotte KY Ng, Luigi M Terracciano
Laboratory Investigation, 2018 - Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study
Carlo Briguori, Cristina Quintavalle, Francesca D'Alessio, Michael Donahue, Giuseppina Roscigno, Francesca De Micco, Amelia Focaccio, Gabriella Visconti, Luigi del Vecchio, Rosalinda Madonna, Raffaele De Caterina, Gerolama Condorelli
International Journal of Cardiology, 2017 - High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy
Cristina Quintavalle, Katharina Burmeister, Salvatore Piscuoglio, Luca Quagliata, Eva Karamitopoulou, Romina Sepe, Alfredo Fusco, Luigi M. Terracciano, Jesper B. Andersen, Pierlorenzo Pallante, Matthias S. Matter
Molecular Carcinogenesis, 2017 - Liver damage and senescence increases in patients developing hepatocellular carcinoma
Silvia Rey, Cristina Quintavalle, Katharina Burmeister, Diego Calabrese, Manuel Schlageter, Luca Quagliata, Gieri Cathomas, Joachim Diebold, Alfredo Molinolo, Markus H Heim, Luigi M Terracciano, Matthias S Matter
Journal of Gastroenterology and Hepatology Australia, 2017 - RYK promotes the stemness of glioblastoma cells via the WNT/β-catenin pathway
Assunta Adamo, Danilo Fiore, Fabio De Martino, Giuseppina Roscigno, Alessandra Affinito, Elvira Donnarumma, Ilaria Puoti, Lucia Ricci Vitiani, Roberto Pallini, Cristina Quintavalle, Gerolama Condorelli
Oncotarget, 2017 - MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer
Giuseppina Roscigno, Ilaria Puoti, Immacolata Giordano, Elvira Donnarumma, Valentina Russo, Alessandra Affinito, Assunta Adamo, Cristina Quintavalle, Matilde Todaro, Maria dM Vivanco, Gerolama Condorelli
Oncotarget, 2017 - Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer
Elvira Donnarumma, Danilo Fiore, Martina Nappa, Giuseppina Roscigno, Assunta Adamo, Margherita Iaboni, Valentina Russo, Alessandra Affinito, Ilaria Puoti, Cristina Quintavalle, Anna Rienzo, Salvatore Piscuoglio, Renato Thomas, Gerolama Condorelli
Oncotarget, 2017 - Phosphoprotein enriched in diabetes (Ped/pea15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib
Cristina Quintavalle, Sravanth Kumar Hindupur, Luca Quagliata, Pierlorenzo Pallante, Cecilia Nigro, Gerolama Condorelli, Jesper Bøje Andersen, Katrin Elisabeth Tagscherer, Wilfried Roth, Francesco Beguinot, Markus Hermann Heim, Charlotte Kiu Yan Ng, Salvatore Piscuoglio, Matthias Sebastian Matter
Cell Death and Disease, 2017 - Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial
Carlo Briguori, Rosalinda Madonna, Marco Zimarino, Paolo Calabrò, Cristina Quintavalle, Maria Salomone, Gerolama Condorelli, Raffaele De Caterina
Cardiovascular Drugs and Therapy, 2016 - Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention
Dominik Witzigmann, Luca Quagliata, Susanne H. Schenk, Cristina Quintavalle, Luigi M. Terracciano, Jörg Huwyler
Hepatology Research, 2016 - Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype
Matthias S. Matter, Jens U. Marquardt, Jesper B. Andersen, Cristina Quintavalle, Nikolay Korokhov, et al.
Hepatology, 2016 - UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients
Nunzio Antonio Cacciola, Chiara Calabrese, Umberto Malapelle, Gianluca Pellino, Alfonso De Stefano, Romina Sepe, Roberta Sgariglia, Cristina Quintavalle, Antonella Federico, Antonio Bianco, André Uchimura Bastos, Marco Milone, Claudio Bellevicine, Francesco Milone, Chiara Carlomagno, Francesco Selvaggi, Giancarlo Troncone, Alfredo Fusco, Pierlorenzo Pallante
Molecular Carcinogenesis, 2016 - miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS
Danilo Fiore, Elvira Donnarumma, Giuseppina Roscigno, Margherita Iaboni, Valentina Russo, Alessandra Affinito, Assunta Adamo, Fabio De Martino, Cristina Quintavalle, Giulia Romano, Adelaide Greco, Ylermi Soini, Arturo Brunetti, Carlo M. Croce, Gerolama Condorelli
Oncotarget, 2016 - HMGA1 overexpression is associated with a particular subset of human breast carcinomas
Romina Sepe, Salvatore Piscuoglio, Cristina Quintavalle, Valeria Perrina, Luca Quagliata, et al.
Journal of Clinical Pathology, 2016 - Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
Margherita Iaboni, Valentina Russo, Raffaela Fontanella, Giuseppina Roscigno, Danilo Fiore, Elvira Donnarumma, Carla Lucia Esposito, Cristina Quintavalle, Paloma H Giangrande, Vittorio de Franciscis, Gerolama Condorelli
Molecular Therapy Nucleic Acids, 2016 - HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models
Mariacarla Andreozzi, Cristina Quintavalle, David Benz, Luca Quagliata, Matthias Matter, et al.
Neoplasia United States, 2016 - MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b
Giuseppina Roscigno, Cristina Quintavalle, Elvira Donnarumma, Ilaria Puoti, Angel Diaz-Lagares, Margherita Iaboni, Danilo Fiore, Valentina Russo, Matilde Todaro, Giulia Romano, Renato Thomas, Giuseppina Cortino, Miriam Gaggianesi, Manel Esteller, Carlo M. Croce, Gerolama Condorelli
Oncotarget, 2016 - A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer
Julia K. Seibert, Luca Quagliata, Cristina Quintavalle, Thomas G. Hammond, Luigi Terracciano, et al.
Cancer Medicine, 2015 - Erratum: Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury (Circulation: Cardiovascular Interventions (2015) 8 (e002673) DOI: 10.1161/CIRCINTERVENTIONS.115.002673)
Circulation Cardiovascular Interventions, 2015 - Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury
Cristina Quintavalle, Chiara Viviani Anselmi, Francesca De Micco, Giuseppina Roscigno, Gabriella Visconti, Bruno Golia, Amelia Focaccio, Bruno Ricciardelli, Enzo Perna, Laura Papa, Elvira Donnarumma, Gerolama Condorelli, Carlo Briguori
Circulation Cardiovascular Interventions, 2015 - Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention: Editorial to: “Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells after Percutaneous Coronary Intervention (HIPOCRATES Study)” by A. Eisen et al.
Carlo Briguori, Cristina Quintavalle, Giovanni Napolitano, Gerolama Condorelli
Cardiovascular Drugs and Therapy, 2015 - Contrast-induced acute kidney injury: Potential new strategies
Carlo Briguori, Elvira Donnarumma, Cristina Quintavalle, Danilo Fiore, Gerolama Condorelli
Current Opinion in Nephrology and Hypertension, 2015 - Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction
Carlo G. Tocchetti, Andrea Carpi, Carmela Coppola, Cristina Quintavalle, Domenica Rea, Marika Campesan, Antonella Arcari, Giovanna Piscopo, Clemente Cipresso, Maria Gaia Monti, Claudia De Lorenzo, Claudio Arra, Gerolama Condorelli, Fabio Di Lisa, Nicola Maurea
European Journal of Heart Failure, 2014 - Novel biomarkers for contrast-induced acute kidney injury
Carlo Briguori, Cristina Quintavalle, Elvira Donnarumma, Gerolama Condorelli
Biomed Research International, 2014 - Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells
Cristina Quintavalle, Stefania Di Costanzo, Ciro Zanca, Immaculada Tasset, Alessandro Fraldi, Mariarosaria Incoronato, Peppino Mirabelli, Maria Monti, Andrea Ballabio, Piero Pucci, Ana Maria Cuervo, Gerolama Condorelli
Journal of Cellular Physiology, 2014 - Therapeutic strategies to prevent contrast-induced acute kidney injury
Cristina Quintavalle, Elvira Donnarumma, Danilo Fiore, Carlo Briguori, Gerolama Condorelli
Current Opinion in Cardiology, 2013 - Endothelial progenitor cells in coronary artery disease
Michael Donahue, Cristina Quintavalle, Giovanni Alfonso Chiariello, Gerolama Condorelli, Carlo Briguori
Biological Chemistry, 2013 - miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells
Cristina Quintavalle, Davide Mangani, Giuseppina Roscigno, Giulia Romano, Angel Diaz-Lagares, Margherita Iaboni, Elvira Donnarumma, Danilo Fiore, Pasqualino De Marinis, Ylermi Soini, Manel Esteller, Gerolama Condorelli
Plos One, 2013 - Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells
C Quintavalle, E Donnarumma, M Iaboni, G Roscigno, M Garofalo, G Romano, D Fiore, P De Marinis, C M Croce, G Condorelli
Oncogene, 2013 - Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay
Francesca Bettazzi, Ezat Hamid-Asl, Carla Lucia Esposito, Cristina Quintavalle, Nello Formisano, Serena Laschi, Silvia Catuogno, Margherita Iaboni, Giovanna Marrazza, Marco Mascini, Laura Cerchia, Vittorio De Franciscis, Gerolama Condorelli, Ilaria Palchetti
Analytical and Bioanalytical Chemistry, 2013 - Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury
Cristina Quintavalle, Danilo Fiore, Francesca De Micco, Gabriella Visconti, Amelia Focaccio, Bruno Golia, Bruno Ricciardelli, Elvira Donnarumma, Antonio Bianco, Maria Assunta Zabatta, Giancarlo Troncone, Antonio Colombo, Carlo Briguori, Gerolama Condorelli
Circulation, 2012 - MiR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP
C Quintavalle, M Garofalo, C Zanca, G Romano, M Iaboni, M del Basso De Caro, J C Martinez-Montero, M Incoronato, G Nuovo, C M Croce, G Condorelli
Oncogene, 2012 - Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli
Translational Lung Cancer Research, 2012 - MiR221/222 in cancer: Their role in tumor progression and response to therapy
M. Garofalo, C. Quintavalle, G. Romano, C. M. Croce, G. Condorelli
Current Molecular Medicine, 2012 - Epigenetic Regulation of miR-212 Expression in Lung Cancer
Mariarosaria Incoronato, Loredana Urso, Ana Portela, Mikko O. Laukkanen, Ylermi Soini, Cristina Quintavalle, Simona Keller, Manel Esteller, Gerolama Condorelli
Plos One, 2011 - Recent advance in biosensors for microRNAs detection in cancer
Silvia Catuogno, Carla L. Esposito, Cristina Quintavalle, Laura Cerchia, Gerolama Condorelli, Vittorio De Franciscis
Cancers, 2011 - In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis
C Quintavalle, M Brenca, F De Micco, D Fiore, S Romano, M F Romano, F Apone, A Bianco, M A Zabatta, G Troncone, C Briguori, G Condorelli
Cell Death and Disease, 2011 - "ApoptomiRs" in vascular cells: Their role in physiological and pathological angiogenesis
Cristina Quintavalle, Michela Garofalo, Carlo M. Croce, Gerolama Condorelli
Vascular Pharmacology, 2011 - Nephrotoxicity of contrast media and protective effects of acetylcysteine
Carlo Briguori, Cristina Quintavalle, Francesca De Micco, Gerolama Condorelli
Archives of Toxicology, 2011 - PED interacts with Rac1 and regulates cell migration/invasion processes in human non-small cell lung cancer cells
Ciro Zanca, Flora Cozzolino, Cristina Quintavalle, Stefania Di Costanzo, Lucia Ricci‐Vitiani, Margherita Santoriello, Maria Monti, Piero Pucci, Gerolama Condorelli
Journal of Cellular Physiology, 2010 - miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED
Mariarosaria Incoronato, Michela Garofalo, Loredana Urso, Giulia Romano, Cristina Quintavalle, Ciro Zanca, Margherita Iaboni, Gerald Nuovo, Carlo Maria Croce, Gerolama Condorelli
Cancer Research, 2010 - C-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3Β activity
C Quintavalle, M Incoronato, L Puca, M Acunzo, C Zanca, G Romano, M Garofalo, M Iaboni, C M Croce, G Condorelli
Cell Death and Differentiation, 2010 - Akt regulates drug-induced cell death through Bcl-w downregulation
Michela Garofalo, Cristina Quintavalle, Ciro Zanca, Assunta De Rienzo, Giulia Romano, Mario Acunzo, Loredana Puca, Mariarosaria Incoronato, Carlo M. Croce, Gerolama Condorelli
Plos One, 2008 - PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer
Ciro Zanca, Michela Garofalo, Cristina Quintavalle, Giulia Romano, Mario Acunzo, Pia Ragno, Nunzia Montuori, Mariarosaria Incoronato, Luigi Tornillo, Daniel Baumhoer, Carlo Briguori, Luigi Terracciano, Gerolama Condorelli
Journal of Cellular and Molecular Medicine, 2008 - Contrast agents and renal cell apoptosis
G. Romano, C. Briguori, C. Quintavalle, C. Zanca, N. V. Rivera, A. Colombo, G. Condorelli
European Heart Journal, 2008 - MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
M Garofalo, C Quintavalle, G Di Leva, C Zanca, G Romano, C Taccioli, C G Liu, C M Croce, G Condorelli
Oncogene, 2008 - Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis
Michela Garofalo, Giulia Romano, Cristina Quintavalle, Maria Fiammetta Romano, Federico Chiurazzi, Ciro Zanca, Gerolama Condorelli
International Journal of Cancer, 2007
